Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies-Reference-Cited by-同舟云学术

Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies

Published:2024-01-02 Issue:1 Volume:134 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Salabarria Stephanie M.,Corti Manuela,Coleman Kirsten E.^ORCID,Wichman Megan B.^ORCID,Berthy Julie A.,D’Souza Precilla,Tifft Cynthia J.^ORCID,Herzog Roland W.,Elder Melissa E.,Shoemaker Lawrence R.,Leon-Astudillo Carmen,Tavakkoli Fatemeh,Kirn David H.,Schwartz Jonathan D.,Byrne Barry J.^ORCID

Funder

College of Medicine, University of Florida

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/173510/files/pdf

Reference41 articles.

1. Sherafat R. Toxicity risks of adeno-associated virus (AAV) vectors for gene therapy (GT). Paper presented at: FDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) Meeting #70; September 2–3, 2021; Virtual. https://www.fda.gov/media/151969/download Accessed November 1, 2023

2. Current Clinical Applications of In Vivo Gene Therapy with AAVs

3. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy

4. Adeno-associated virus vector as a platform for gene therapy delivery

5. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving the safety of systemic viral gene therapy;Journal of Clinical Investigation;2024-01-02